Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

Questions to Ask Biologic Sales Reps About FDA 361

Published November 15, 2026

Regulatory Framework
21 CFR Part 1271

The federal regulation governing human cells, tissues, and cellular and tissue-based products (HCT/Ps), defining the boundary between Section 361 and Section 351 products.

Qualification Criteria
4 Core Conditions

Under 21 CFR 1271.10(a), an HCT/P must satisfy all four specific conditions—including minimal manipulation and homologous use—to be regulated solely under Section 361.

Verification Standard
FEI Number Lookup

The FDA Establishment Identifier (FEI) allows practice administrators to bypass private-label branding and audit the actual tissue processor in the public HCTERS database.

When evaluating regenerative medicine vendors, the most important questions to ask biologic sales reps about FDA 361 compliance focus on verifying the tissue bank's FDA Establishment Registration, confirming how the product meets the four regulatory criteria under 21 CFR Part 1271.10(a), and reviewing documentation for donor screening and minimal manipulation. Practice managers should also request copies of the manufacturer's inspection history and clarify exact cold-chain logistics before signing any purchasing agreements. Requiring documented proof rather than relying on verbal assurances protects both the clinical license of the physicians and the operational continuity of the practice.

Understanding the Regulatory Landscape for Practice Managers

For medical practice administrators, procuring human cells, tissues, and cellular and tissue-based products (HCT/Ps) carries a significantly higher compliance burden than ordering standard medical supplies. Since the conclusion of the FDA's enforcement discretion period in May 2021, regulatory scrutiny on birth-tissue allografts, amniotic fluid, Wharton's Jelly, and exosome products has intensified.

The core distinction in regenerative procurement lies between Public Health Service (PHS) Act Section 361 products and Section 351 products. Section 361 products are regulated solely under 21 CFR Part 1271 and do not require premarket approval or an Investigational New Drug (IND) application, provided they meet strict criteria. Section 351 products are regulated as drugs or biological products and require an active IND or a Biologics License Application (BLA) to be lawfully marketed and distributed.

Many sales representatives present their entire catalog of biologics as "FDA registered" or "361 compliant." However, registration of a tissue establishment with the FDA does not mean the agency has approved the specific product being sold or agreed with the manufacturer's self-designation as a 361 HCT/P. As the gatekeeper for vendor onboarding, the practice manager must separate promotional language from verifiable regulatory documentation.

Core Questions to Ask Biologic Sales Reps About FDA 361 Compliance

When a representative presents a new allograft, cellular matrix, or acellular product, administrators should use a standardized vetting protocol. Below is an operational checklist of questions to ask during the procurement review.

1. Registration and Manufacturing Lineage

  • "What is the exact Legal Establishment Name and FDA Establishment Identifier (FEI) number of the processing lab?" Distributors often private-label products. You need the name of the actual processing facility so you can look them up directly in the FDA's Human Cell and Tissue Establishment Registration (HCTERS) public database.
  • "Has the processing facility or the brand owner ever received an FDA Warning Letter, an Untitled Letter, or a Form FDA 483?" If the rep says no, verify this independently through the FDA's compliance database. If a facility has received a 483 during a routine inspection, ask to see the documented corrective action plan.
  • "Is the tissue bank accredited by the American Association of Tissue Banks (AATB)?" While AATB accreditation is voluntary and separate from FDA registration, it indicates adherence to established industry standards for tissue recovery, processing, and Donor Eligibility Determination.

2. The Four Criteria of 21 CFR 1271.10(a)

To qualify as a Section 361 HCT/P, a product must meet all four conditions outlined in 21 CFR 1271.10(a). Ask the representative to provide the manufacturer's regulatory rationale for each:

  • Minimal Manipulation: "How is this tissue processed, and how does the lab justify that the processing does not alter the original relevant characteristics of the structural tissue (such as decellularization, micronization, or enzymatic digestion)?"
  • Homologous Use: "How does the manufacturer define the homologous function of this tissue in the donor, and what does the package insert state as the intended use in the recipient?" Be cautious if a rep verbally promotes systemic or disease-specific applications while the package insert states the product is solely a structural covering or cushion.
  • No Combination with Other Articles: "Is the tissue combined with any other agents aside from water, crystalloids, or a sterilizing, preserving, or storage agent?"
  • Systemic Effect and Metabolic Activity: "Does the product rely on the metabolic activity of living cells for its primary function?" If the rep claims the vial contains "millions of live, active mesenchymal stem cells" that will regenerate tissue in an orthopedic joint, that claim typically contradicts the regulatory definition of a 361 structural allograft.

3. Marketing Materials vs. Package Inserts

  • "May I have a copy of the actual package insert and Instructions for Use (IFU) prior to placing an order?" Compare the IFU with the glossy marketing brochures. Compliant vendors maintain strict alignment between their promotional sheets and the official package insert.
  • "Does your company provide patient-facing marketing materials, and have they been reviewed by healthcare regulatory counsel?" Both the FDA and the Federal Trade Commission (FTC) monitor clinic websites and brochures for unsubstantiated therapeutic claims.

4. Cold-Chain Logistics and Lot Traceability

  • "How is cold-chain integrity validated from the lab to our clinic door?" Ask whether shipments include temperature indicators, what the protocol is if a Friday delivery is delayed over the weekend, and whether your clinic requires a specialized ultra-low temperature freezer or liquid nitrogen Dewar.
  • "What documentation is included with each unit for our allograft tissue log?" Every unit should arrive with a Certificate of Analysis (CoA) or Donor Eligibility summary, clear lot numbers, expiration dates, and a tissue tracking card to return to the processor.

Red Flags in Vendor Responses

During your vendor evaluation, how a sales representative responds is just as informative as the documents they provide. Practice managers should halt the onboarding process if they encounter any of the following red flags:

  • Conflating "FDA Registered" with "FDA Approved": Any rep who implies that an FDA tissue bank registration equates to FDA approval of the product's safety, efficacy, or 361 classification is either poorly trained or intentionally misleading your staff.
  • Verbal Claims That Contradict the Label: If the package insert describes an amniotic membrane as a wound covering, but the rep coaches your staff on how to inject it intravenously or intra-articulately while promising specific clinical outcomes, the vendor is exposing your practice to compliance liability.
  • Refusal to Disclose the Processing Lab: If a distributor claims their manufacturing partner is "proprietary" and refuses to share the FEI number or donor screening summaries before a contract is signed, walk away.
  • Guarantees of Third-Party Reimbursement: Coverage for regenerative biologics varies widely by payer, setting of care, and Q-code status. Vendors promising effortless insurance reimbursement without providing verified billing guidance and payer policy documentation create major audit risks.

Clinical Perspective: Aligning Physician Goals with Operational Compliance

While practice managers focus on vendor legitimacy, chain of custody, and liability protection, the treating physicians—whether in orthopedics, pain management, or aesthetics—are focused on patient safety, handling characteristics, and clinical reproducibility. Bringing physicians into the final stage of the vendor review ensures that operational compliance aligns with clinical expectations.

Physicians should evaluate the biological plausibility and consistency of the product alongside its regulatory status. When a sales rep claims a cryo-preserved allograft contains high concentrations of viable stem cells, the clinician should recognize the tension between that claim and Section 361 criteria. Furthermore, physicians should review the processor's donor screening panel ( verifying testing for HIV, Hepatitis B and C, syphilis, WNV, and Zika, among other communicable diseases) and sterilization or aseptic processing methods.

For clinics seeking to avoid the regulatory ambiguity of certain third-party allogeneic tissues altogether, clinicians often combine autologous point-of-care systems—such as Platelet-Rich Plasma (PRP)—with non-invasive regenerative devices like extracorporeal shockwave therapy (ECSWT) or high-power laser therapy. Because autologous blood products prepared and used during the same surgical procedure or clinic visit generally fall under different regulatory exemptions, pairing autologous options with cleared capital equipment offers a straightforward compliance profile while still supporting comprehensive care protocols for regenerative medicine doctors.

What This Means for Your Practice

Establishing a formal procurement protocol for regenerative products protects your practice from supply chain disruptions, financial loss from seized or recalled inventory, and regulatory scrutiny. Before ordering from a new biologic representative, take these concrete steps:

  1. Build a Vendor Qualification File: Create a digital folder for every biologic vendor containing their current FDA Establishment Registration printout, AATB certificate (if applicable), a sample Certificate of Analysis, and the unredacted Package Insert.
  2. Audit Your Current Inventory and Marketing: Review your clinic's website, social media, and patient intake forms to ensure your staff is not repeating unverified sales rep claims (such as referring to acellular birth-tissue products as "live stem cell therapy").
  3. Standardize Your Tissue Log: Ensure your medical assistants and nurses have a strict standard operating procedure (SOP) for logging receipt temperature, lot numbers, expiration dates, and patient assignment for every allograft that enters the building.
  4. Partner with Transparent Distributors: Work with established medical distributors who openly provide regulatory documentation, hold proper state device distribution licenses, and respect the boundary between product supply and the practice of medicine.

If your practice is evaluating its current regenerative supply chain or looking to compare compliant biologic options alongside capital equipment modalities, our team can help you review the operational requirements. Reach out through our contact page to schedule a consultation with a Dallas Regenerative Solutions specialist.

Frequently asked questions

Does an FDA registration certificate mean a biologic product is FDA approved as a 361 tissue?
No. An FDA Establishment Registration simply means the processing facility has notified the FDA that it recovers, processes, stores, or distributes human tissue. Under 21 CFR Part 1271, tissue banks self-designate their products as Section 361 HCT/Ps during registration, and the FDA does not pre-approve or verify this classification at the time of registration.
How can a practice manager verify a tissue bank's FDA registration independently?
Practice managers can verify a facility's status using the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database online. By entering the processor's legal name or FDA Establishment Identifier (FEI) number, you can confirm whether their registration is active and view the specific types of tissues and functions they have listed.
What are the four criteria required for a product to qualify under PHS Act Section 361?
Under 21 CFR 1271.10(a), an HCT/P must meet four criteria to be regulated solely under Section 361: it must be minimally manipulated; it must be intended for homologous use only as reflected by the labeling and advertising; its manufacture must not involve the combination of the cells or tissues with another article (with limited exceptions like water or preserving agents); and it must either not have a systemic effect and not depend on the metabolic activity of living cells for its primary function, or if it does, it must be for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.
Why is it a red flag if a sales rep claims an amniotic or Wharton's Jelly product contains live stem cells?
If an allogeneic birth-tissue product relies on the metabolic activity of living cells for its primary function in an unrelated recipient, it generally fails the fourth criterion of 21 CFR 1271.10(a) and is regulated as a Section 351 biological drug requiring an IND or BLA. Therefore, a sales rep claiming a product is both a "361 compliant product" and works via "millions of live, active stem cells" is making contradictory regulatory statements.
What documentation should arrive with every biologic shipment to our clinic?
Every shipment of human allograft tissue should include a packing slip with lot and serial numbers, a temperature monitoring indicator or validation log for cold-chain verification, the official Package Insert (Instructions for Use), a Donor Eligibility summary or Certificate of Analysis, and a tissue recipient tracking record to be returned to the tissue bank.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →